Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...

This patent pertains to the repeat dose regimen of CARDAMYST™, which demonstrated efficacy in the RAPID Phase 3 study for paroxysmal supraventricular tachycardia (PSVT). The issuance of this ...

It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid ...

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT ... to initiate Phase 3 Study in AFib-RVR in H1 2025 MONTREAL and CHARLOTTE ...

This patent pertains to the repeat dose regimen of CARDAMYST™, which demonstrated efficacy in the RAPID Phase 3 study for paroxysmal supraventricular tachycardia ... with PSVT and atrial fibrillation ...

ESCAMBIA COUNTY, Fla. -- More than 12 million Americans are estimated to suffer from atrial fibrillation by 2030, according to doctors. Now, there's a new provider hoping to make treatment more ...